We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Rockwell Medical (RMTI) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Rockwell Medical (RMTI - Free Report) closed at $2.06, marking a +1.48% move from the previous day. This move outpaced the S&P 500's daily loss of 1.37%. Meanwhile, the Dow lost 1.29%, and the Nasdaq, a tech-heavy index, lost 1.87%.
Heading into today, shares of the maker of products used in the treatment of kidney disease and anemia had lost 13.62% over the past month, lagging the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Investors will be hoping for strength from Rockwell Medical as it approaches its next earnings release. The company is expected to report EPS of -$0.12, up 70% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.67 million, up 26.65% from the year-ago period.
RMTI's full-year Zacks Consensus Estimates are calling for earnings of -$0.43 per share and revenue of $86.08 million. These results would represent year-over-year changes of +77.25% and +18.23%, respectively.
Investors might also notice recent changes to analyst estimates for Rockwell Medical. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Rockwell Medical currently has a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RMTI in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Rockwell Medical (RMTI) Gains As Market Dips: What You Should Know
In the latest trading session, Rockwell Medical (RMTI - Free Report) closed at $2.06, marking a +1.48% move from the previous day. This move outpaced the S&P 500's daily loss of 1.37%. Meanwhile, the Dow lost 1.29%, and the Nasdaq, a tech-heavy index, lost 1.87%.
Heading into today, shares of the maker of products used in the treatment of kidney disease and anemia had lost 13.62% over the past month, lagging the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Investors will be hoping for strength from Rockwell Medical as it approaches its next earnings release. The company is expected to report EPS of -$0.12, up 70% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.67 million, up 26.65% from the year-ago period.
RMTI's full-year Zacks Consensus Estimates are calling for earnings of -$0.43 per share and revenue of $86.08 million. These results would represent year-over-year changes of +77.25% and +18.23%, respectively.
Investors might also notice recent changes to analyst estimates for Rockwell Medical. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Rockwell Medical currently has a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RMTI in the coming trading sessions, be sure to utilize Zacks.com.